Millions awarded for better cancer treatment using radioactive isotopes and AI

The NWO Perpspectief-grands have been awarded to nine new consortia, two of which are led by the Radboudumc and Radboud University in Nijmegen.

Targeting cancer with radiation from within
UNderstanding the RAdiobiology of therapeutic medical radioNUclides (UNRANU)
Link to video

Cancer is a leading cause of death worldwide. Most patients with metastasised disease can no longer be cured. So-called radionuclide therapy can substantially improve their survival. Patients undergoing this therapy are administered substances containing radioactive atoms – the radionuclide. These substances will specifically move to and bind to the tumour, irradiating it from the inside. The UNRANU programme develops new production routes for these radionuclides, finds the best match between radionuclide and tumour type, determines the optimal treatment dose, and investigates how treatment effectiveness is influenced by the immune system.

Programme leader: Dr Frank Nijsen (Radboudumc)
Knowledge institutes: Erasmus MC, Oncode, RIVM National Institute for Public Health and the Environment, Radboudumc, TU Delft
Companies: AlfaRIM, HUB Organoids, MILabs, NRG, PALLAS, Quirem Medical, Terumo, RTM, Siemens Healthineers, TerThera, URENCO, Von Gahlen, VSL
Other social partners: Meander Medisch Centrum, Nederlandse Leverpatiënten Vereniging, Nederlandse Vereniging van Nucleaire Geneeskunde, Prostaatkanker Stichting, Reiner de Graaf Ziekenhuis, Science Education Hub Radboud University, Stichting darmkanker

Source: 40 million euros for research on innovative technologies in 9 new Perspectief programmes | NWO


Selecting the optimal cancer treatment with artificial intelligence
PersOn: Explainable, Maintainable, and Trustworthy Decision Support Systems for Personalised Care in Oncology
Link to video

Each year, more people are being diagnosed with cancer. They will often receive a standardized medical treatment that disregards the patient’s expectations about their quality of life during and after treatment. The PersOn programme uses artificial intelligence to analyse all data available – of the type of cancer as well as the individual patient – to predict the expected outcome of various treatment options. Using this information, the clinician and the patient will jointly choose the personalised care path that maximises the probability of having the highest quality of life.

Programme leader: Dr. Johan Kwisthout (Radboud University)
Knowledge institutes: Amsterdam UMC, Eindhoven University of Technology, Maastricht University, Netherlands Comprehensive Cancer Organisation, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Open Universiteit, Radboud University, Radboudumc, TNO, Utrecht University, VU Amsterdam
Companies: Chipsoft, Connected Care, CZ, Hugin Expert A/S, ICTRecht, Info Support, Maastro Clinic, Machine2Learn, Open Walnoot, Orikami, Privacy Company, Saddle Point Science Europe, We Are Not
Other social partners: Isala Ziekenhuis Zwolle, Nederlandse Federatie van Kankerpatiëntenorganisaties

Source: 40 million euros for research on innovative technologies in 9 new Perspectief programmes | NWO